Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer.  A phase III trial of the National Cancer Institute of Cancada Clinical Trials Group (NCIC-CTG)

Reviewer: Ryan Smith , MD
OncoLink
Ultima Vez Modificado: 15 de mayo del 2005

Translation for this article does not exist